Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for COVID-19 Disease
| | | |

Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for COVID-19 Disease

On Jul. 10, 2025, Moderna announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental…

NIH will reinstate 900 grants in response to court order
| | | | | | | | | | | | | | | | | | | | |

NIH will reinstate 900 grants in response to court order

On Jun. 25, 2025, the National Institutes of Health (NIH) moved to reinstate about 900 grants that a…

Novavax’s COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses in Phase 3 Trial
| | | | |

Novavax’s COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses in Phase 3 Trial

On Jun. 11, 2025, Novavax announced results of the initial cohort of its COVID-19-Influenza Combination (CIC) and stand-alone trivalent…